New offering integrates advanced in vitro models to identify neurotoxic effects earlier in development
Cellectricon, a Sweden-based neuroscience drug discovery services company, has launched its new Neurotoxicity Testing Services, expanding its established neuroscience platform to support early-stage safety evaluation of drug candidates.
The launch reflects growing demand from the neuroscience community for early neurotoxicity screening tools. The new service enables developers to detect potential neurotoxic effects sooner, helping reduce development risks, shorten timelines, and improve decision-making confidence.
Cellectricon’s new service leverages its validated in vitro neuronal models and combines multiple assay technologies, including:
These technologies allow the assessment of acute and chronic neurotoxicity endpoints, such as neuronal excitability, neurite outgrowth, metabolic activity, cytokine release, and cellular phenotype.
By integrating high-throughput formats with physiologically relevant models, Cellectricon aims to help drug developers front-load neurotoxicity evaluation—particularly valuable for emerging therapeutic modalities such as oligonucleotide-based drugs.
“In recent years, we’ve seen growing demand for early-stage neurotoxicity testing—particularly from teams developing oligonucleotide-based drugs, who often face challenges in obtaining reliable, accurate assessments,” said Mattias Karlsson, Chief Executive Officer at Cellectricon.
He added that the company’s existing validated assays were well suited to address this gap, allowing Cellectricon to provide a robust, translationally relevant solution for safety testing in neuroscience drug discovery.
Cellectricon will showcase its new Neurotoxicity Testing Services and its Neuroscience Service Modules at:
Additionally, the company will host a live webinar titled “In Vitro Neuronal Models for Assessment of Acute and Delayed Onset Toxicity Effects of Oligonucleotide-Based Drugs” on Wednesday, November 12, from 16:00–16:30 CET. The session will highlight how in vitro neuronal models can improve translational relevance and de-risk neurotoxicity challenges in oligonucleotide drug development.
Founded in 2003 and headquartered in Mölndal, Sweden, Cellectricon provides specialized neuroscience drug discovery services focused on scientifically robust and physiologically relevant in vitro research solutions. The company partners with global biopharma and biotech clients to advance discovery and development in neurology and CNS disorders.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!